Upcoming Agents for the Treatment of Schizophrenia

  title={Upcoming Agents for the Treatment of Schizophrenia},
  author={Delia Bishara and David Taylor},
Since the introduction of a group of atypical antipsychotics in the 1990s, there has been a decline in the rate of new antipsychotics being introduced into clinical practice. However, with increasing safety and efficacy concerns over currently available drugs and a dearth of options available for atypical depot formulations, there is a considerable need for the development of new formulations and agents. This review examines the profile of seven antipsychotic drugs currently in the premarketing… 

New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?

Long-term, head-to-head comparative studies are required to clarify the risk/benefit profiles of the newer antipsychotics and their roles in the treatment of schizophrenia.

Evaluation of the clinical efficacy of asenapine in schizophrenia

Asenapine is a recently approved agent with an acceptable cardiometabolic profile and exhibits similar efficacy as other antipsychotic medications, primarily on positive symptoms of schizophrenia.

Critical appraisal of lurasidone in the management of schizophrenia

Lurasidone is a new atypical antipsychotic in the benzoisothiazoles class of chemicals. Like most second-generation antipsychotics it is a full antagonist at dopamine D2 and serotonin 5-HT2A

New atypical antipsychotics for schizophrenia: iloperidone

In double-blind phase III trials iloperidone reduced the symptoms of schizophrenia at oral doses from 12 to 24 mg and was more effective than placebo in reducing positive and negative syndrome total score and Brief Psychiatric Rating scale scores; it was as effective as haloperidol and risperidone in post-hoc analysis.

Paliperidone Extended-Release: Safety and Tolerability from a Metabolic Profile Perspective

The ER formulation of paliperidone may offer potential advantages over atypical antipsychotics such as risperidone, particularly with regard to side effects and compliance, but comparative studies are needed.

Neurobiological Background for the Development of New Drugs in Schizophrenia

Research in the antipsychotics field has developed also by exploring pathways that are beyond the spectrum of clozapine, and among the most promising mechanisms are those based on the glutamatergic hypothesis of schizophrenia.

Iloperidone: A new drug for the treatment of schizophrenia.

  • Sally A. ArifMelissa Mitchell
  • Medicine, Psychology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
Iloperidone may be a viable and safe option for the treatment of schizophrenia in adult patients, especially for patients who cannot tolerate other antipsychotic agents.

Efficacy and safety of long acting injectable atypical antipsychotics: a review.

The literature on LAI atypical antipsychotics will be reviewed and practical advice will be given concerning the use of these drugs in the clinical practice.

Blonanserin: a review of its use in the management of schizophrenia.

Clinical data suggest that blonanserin is an effective and generally well tolerated option for the short-term treatment of schizophrenia and for those requiring longer-term therapy.

Iloperidone—A Second-Generation Antipsychotic for the Treatment of Acute Schizophrenia

Iloperidone is an effective treatment for the symptoms of acute schizophrenia in adults and comparative effectiveness with other pharmacologic treatments of schizophrenia, long-term efficacy, and long- term safety is needed.



Pharmacological and molecular targets in the search for novel antipsychotics

The recent enthusiasm among clinicians for the so‐called "atypical antipsychotics" has both improved treatment for schizophrenic patients and provided a welcome stimulus for basic research on

Risperidone in the treatment of schizophrenia.

Risperidone has shown very good effectiveness and safety in patients with schizophrenia, and was able to discontinue current antipsychotic medications.

The Role of Serotonin in Antipsychotic Drug Action

  • H. Meltzer
  • Psychology, Medicine
  • 1999

A review of the effect of atypical antipsychotics on weight

  • H. Nasrallah
  • Psychology, Medicine
  • 2003

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.

The pipeline and future of drug development in schizophrenia

The current pipeline of drugs for schizophrenia is discussed, outlining many of the strategies and targets currently under investigation for the development of new schizophrenia drugs and highlighting the importance of developing new paradigms for drug discovery in schizophrenia.

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

Olanzapine is a potent 5- HT2 blocker and shows a higher 5-HT2 than D2 occupancy at all doses, however, its D1 occupancy is higher than that of clozapine and similar to that of risperidone.

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

A review examines the potential contribution of different receptors to metabolic side effects associated with atypical antipsychotic treatment for all seven agents currently marketed in the United States and another agent in clinical development at the time of this publication.

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.

Aripiprazole is the first non-D2 receptor antagonist with clear antipsychotic effects and represents a novel treatment development for psychotic disorders.

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.

The findings raise the question of whether continuously high D(2) blockade is necessary for obtaining an antipsychotic response and future studies aimed at evaluating the relative merits of "transiently high" versus "continuously high" D( 2) occupancy are warranted.